Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
CHEYENNE, WY / ACCESS Newswire / June 9, 2025 / Row64, creators of the only visual real-time business intelligence platform for big data, today announced its $4 million seed funding round led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback